Phase 2 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been confirmed by tissue biopsy or pathology testing to have a type of uterine cancer called low grade endometrial stromal sarcoma (ESS)
- People whose cancer had spread beyond the uterus at the time of diagnosis, or whose tumour was accidentally ruptured during a hysterectomy operation
- People who have been taking a hormone-blocking medication called an aromatase inhibitor (specifically Anastrozole, Exemestane, or Letrozole) for at least 24 months (if no measurable disease was present when treatment started) or at least 36 months (if measurable disease was present when treatment started)
- People whose cancer is currently stable or responding to the aromatase inhibitor treatment at the time of joining the trial
- People with a general health and activity level rated at 2 or below on a standard medical scale, meaning they are able to care for themselves but may not be able to do heavy physical activity (confirm with trial site)
- People covered by health/medical insurance
- People who have signed a consent form agreeing to take part before any trial procedures begin
Who may not be able to join:
- People who are pregnant or breastfeeding
- People currently taking other cancer treatments, whether standard or experimental
- People with serious ongoing health conditions affecting the heart, liver, kidneys, or blood-forming system that could interfere with the trial (as assessed by the trial doctor)
- People who have had a different type of cancer in the past, unless it was a minor skin cancer (basal cell or squamous cell) or a very early-stage cervical condition, or unless they have been cancer-free for at least 3 years
- People taking certain other medications that are not permitted during this trial
- People for whom the study medications are medically unsuitable based on official prescribing guidelines
- People who legally require a guardian or third-party support to make decisions on their behalf (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Isabelle RAY-COQUARD, MD PhD, Centre Leon Berard
Phone: +33478782786
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.